AR049177A1 - Polipeptidos y conjugados de interferon-alfa - Google Patents

Polipeptidos y conjugados de interferon-alfa

Info

Publication number
AR049177A1
AR049177A1 ARP050102059A ARP050102059A AR049177A1 AR 049177 A1 AR049177 A1 AR 049177A1 AR P050102059 A ARP050102059 A AR P050102059A AR P050102059 A ARP050102059 A AR P050102059A AR 049177 A1 AR049177 A1 AR 049177A1
Authority
AR
Argentina
Prior art keywords
polypeptides
conjugates
nucleic acids
interferon
alfa
Prior art date
Application number
ARP050102059A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Maxygen Inc filed Critical Hoffmann La Roche
Publication of AR049177A1 publication Critical patent/AR049177A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Polipéptidos y conjugados de interferon-alfa, y ácidos nucleicos que codifican los polipéptidos. También se incluyen composiciones que comprenden estos polipéptidos, conjugados y ácidos nucleicos; células que contienen o expresan los polipéptidos, los conjugados y los ácidos nucleicos; métodos para preparar los polipéptidos, los conjugados y los ácidos nucleicos; y métodos para usar los polipéptidos, los conjugados y los ácidos nucleicos. Reivindicacion 1: Un polipéptido aislado o recombinante caracterizado porque comprende una secuencia que (a) difiere en entre 1 y 16 posiciones de aminoácidos de SEQ ID No. 1, y (b) comprende una o más sustituciones respecto de SEQ ID No. 1 seleccionadas del grupo que consiste en F48A/L; V51P; F55A; F65A; F68P; L111A; y V114P; donde el polipéptido presenta actividad antiviral.
ARP050102059A 2004-05-19 2005-05-19 Polipeptidos y conjugados de interferon-alfa AR049177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57250404P 2004-05-19 2004-05-19

Publications (1)

Publication Number Publication Date
AR049177A1 true AR049177A1 (es) 2006-07-05

Family

ID=35428915

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102059A AR049177A1 (es) 2004-05-19 2005-05-19 Polipeptidos y conjugados de interferon-alfa

Country Status (14)

Country Link
US (9) US7318918B2 (es)
EP (1) EP1753779A2 (es)
JP (1) JP2008507298A (es)
CN (1) CN101115769A (es)
AR (1) AR049177A1 (es)
AU (1) AU2005245918A1 (es)
BR (1) BRPI0511196A (es)
CA (1) CA2566247A1 (es)
IL (1) IL178470A0 (es)
MX (1) MXPA06013412A (es)
NO (1) NO20065084L (es)
RU (1) RU2006145020A (es)
TW (1) TW200611910A (es)
WO (1) WO2005113592A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537762A (ja) 1999-01-05 2002-11-12 トラスティーズ オブ ボストン ユニバーシティ 改良型核酸クローニング
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
WO2002008408A2 (en) * 2000-07-21 2002-01-31 Trustees Of Boston University Modular vector systems
US7435562B2 (en) * 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
WO2005112586A2 (en) * 2004-05-12 2005-12-01 Fusionone, Inc. Advanced contact identification system
CA2590245A1 (en) 2004-11-11 2006-05-18 Modular Genetics, Inc. Ladder assembly and system for generating diversity
MY167668A (en) * 2005-03-09 2018-09-21 Superlab Far East Ltd Uses of recombinant super-compound interferons
JP2008545393A (ja) 2005-05-18 2008-12-18 マキシジェン， インコーポレイテッド 進歩したインターフェロンαポリペプチド
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
WO2008008808A2 (en) * 2006-07-11 2008-01-17 Modular Genetics Inc. Methods of introducing targeted diversity into nucleic acid molecules
US20100009908A1 (en) * 2006-07-25 2010-01-14 Nozomu Nishi Galectin 9-Polymer Conjugates
US7808342B2 (en) * 2006-10-02 2010-10-05 Skyworks Solutions, Inc. Harmonic phase tuning filter for RF switches
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009006579A1 (en) * 2007-07-05 2009-01-08 Pharmaessentia Corp. Peptide-polymer conjugates
WO2009046080A1 (en) 2007-10-01 2009-04-09 Pharmaessentia Corp. N-terminal modified interferon-alpha
CA2711375C (en) 2008-01-18 2019-04-16 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides
US7954022B2 (en) * 2008-01-30 2011-05-31 Alcatel-Lucent Usa Inc. Apparatus and method for controlling dynamic modification of a scan path
KR20110086705A (ko) * 2008-11-17 2011-07-29 제넨테크, 인크. 생리학적 조건 하에 거대분자의 응집을 감소시키는 방법 및 제제
US8940501B2 (en) 2009-01-30 2015-01-27 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
SG195192A1 (en) 2011-06-02 2013-12-30 Hanmi Science Co Ltd Non-peptidyl polymer-insulin multimer and method for producing the same
WO2013003555A1 (en) 2011-06-28 2013-01-03 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
CN102358897B (zh) * 2011-10-31 2013-02-13 北京三元基因工程有限公司 重组人寡腺苷酸合成酶-1的制备方法
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
EP3006045B3 (en) * 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
RU2650755C1 (ru) * 2017-05-24 2018-04-17 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Способ очистки лекарственного средства пролонгированного действия на основе рекомбинантного аналога интерферона альфа-17 для лечения вирусного гепатита С
IL294901A (en) * 2020-01-24 2022-09-01 Alkermes Pharma Ireland Ltd Methods for purification

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) * 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
ES506955A0 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
IT1167610B (it) 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPS60152058A (ja) * 1984-01-20 1985-08-10 Toshiba Corp 半導体記憶装置
ATE78262T1 (de) * 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US4695626A (en) * 1986-07-29 1987-09-22 Pfizer Inc. 1-aza-4,5-dithiabicyclo [4.2.0] oct-2-en-8-one-2 carboxylate esters
SG52537A1 (en) 1990-10-17 1998-09-28 Amgen Inc Methods and compositions for the treatment of cell proliferation disorders
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6007805A (en) 1994-03-07 1999-12-28 Imperial College Of Science And Technology Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
EP1881005B1 (en) 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
BR122013003013B8 (pt) 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
WO2000052153A2 (en) * 1999-03-02 2000-09-08 Maxygen, Inc. Method to identify ligands for orphan receptors
DK1187852T3 (da) 1999-05-19 2007-11-26 Merck Patent Gmbh Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
EP1238082A2 (en) 1999-10-07 2002-09-11 Maxygen, Inc. Ifn-alpha homologues
CA2390292A1 (en) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
EP1284987B1 (en) 2000-05-16 2007-07-18 Bolder Biotechnology, Inc. Methods for refolding proteins containing free cysteine residues
AU2002223350A1 (en) 2000-12-01 2002-06-11 Eleanor N. Fish Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
AU2003293668A1 (en) 2002-11-15 2004-06-15 F. Hoffmann-La Roche Ag Positional isomers of peg ifn alpha 2a
CA2504267A1 (en) 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates

Also Published As

Publication number Publication date
IL178470A0 (en) 2007-02-11
US20070225205A1 (en) 2007-09-27
US20080031853A1 (en) 2008-02-07
US7541436B2 (en) 2009-06-02
BRPI0511196A (pt) 2007-12-04
TW200611910A (en) 2006-04-16
AU2005245918A1 (en) 2005-12-01
US20080076710A1 (en) 2008-03-27
CN101115769A (zh) 2008-01-30
US20070225204A1 (en) 2007-09-27
MXPA06013412A (es) 2007-01-23
NO20065084L (no) 2006-12-01
US7541163B2 (en) 2009-06-02
US20070025966A1 (en) 2007-02-01
US7537755B2 (en) 2009-05-26
RU2006145020A (ru) 2008-06-27
US20080171363A1 (en) 2008-07-17
US20070020734A1 (en) 2007-01-25
US7318918B2 (en) 2008-01-15
WO2005113592A2 (en) 2005-12-01
EP1753779A2 (en) 2007-02-21
WO2005113592A3 (en) 2006-04-06
US7531630B2 (en) 2009-05-12
US20070020235A1 (en) 2007-01-25
US20050266465A1 (en) 2005-12-01
US7531324B2 (en) 2009-05-12
JP2008507298A (ja) 2008-03-13
CA2566247A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
ES2545457T3 (es) Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
ATE400656T1 (de) Mini-dystrophin nukleinsäure- und peptidsequenzen
ES2513716T3 (es) Enzimas lecitina-colesteros acitransferasa modificadas
DK2014678T3 (da) KDR-peptider og vacciner indeholdende disse
ES2507094T3 (es) Proteína específica del timo
ES2536974T3 (es) Péptidos de epítopos del receptor de EGF y usos de los mismos
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
EP2573109A3 (en) Peptide vaccines comprising Seq Id 101, 80 or 100 for cancers expressing tumor-associated antigens
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
AR050095A1 (es) Secuencias de subinidades pequenas de sintasa acetohidroxiacida de monocotiledoneas y metodos de uso.
MX2010004371A (es) Proteasa de streptomyces.
NO20052363L (no) Interferon-alfa polypeptider og konjugater
IL187293A0 (en) Recombinant n-glycosylated proteins from procaryotic cells
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
CO6251278A2 (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol
NZ580378A (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
AR070491A1 (es) Variante de enzima lipolitica con estabilidad aumentada y polinucleotidos que la codifican
CY1114526T1 (el) Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
AR087719A2 (es) Celula de planta transformada, cultivo de tejidos y planta transgenica
DK1276763T3 (da) Anti-fryseproteiner, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
FB Suspension of granting procedure